WHO 批准两项新的埃博拉疫苗临床试验
WHO approves clinical trials on two new Ebola vaccines
WHO 批准了两项针对 Bundibugyo 病毒的新埃博拉疫苗临床试验,由牛津大学和印度血清研究所开发的 ChAdOx1 BDBV 和 Moderna 的 mRNA-1469。试验由刚果民主共和国的国家生物医学研究所领导,合作伙伴包括 WHO。
The World Health Organization on Wednesday approved clinical trials for two new Ebola vaccines, as doctors fight to control an outbreak in Africa that has killed more than 5,300 people.
"Last month, a vaccine trial began using the Ervebo vaccine, which is approved for Ebola virus, but not for Bundibugyo virus" ravaging the Democratic Republic of Congo, WHO chief Tedros Adhanom Ghebreyesus told reporters.
"Today, WHO expert groups are recommending adding two vaccine candidates to the trial," he added.
Those two—ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469—were developed specifically for the Bundibugyo virus, he explained.
The DRC's National Institute for Biomedical Research is leading the trial, backed by partners including WHO, said Tedros.
"Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trusted engagement with communities," he added.
On Monday, the Africa Centres for Disease Control and Prevention (Africa CDC) said Africa's ongoing Ebola epidemic had killed more than 5,300 people, the vast majority of them in the Democratic Republic of Congo.
A total of 10,444 cases have been confirmed, with a fatality rate of more than 50%, it added.
Key medical concepts
Who's behind this story?
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 AFP
Citation: WHO approves clinical trials on two new Ebola vaccines (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-clinical-trials-ebola-vaccines.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com